Table 3.

Frequencies of HLA-B and HLA-DRB1 were determined for DOBV-infected patients with different disease progressions and compared among groups

Allele	Frequency (%) among individuals in indicated group				P value (relative risk)a
	Control (n = 131)	Outcome			Fatal/severe	Fatal/mild	Severe/mild	Fatal/control	Severe/control	Mild/control
		Fatal (n = 7)	Severe (n = 31)	Mild (n = 29)
B*07	24.4	14.3	29.0	10.3	NS	NS	NS	NS	NS	NS
B*08	13.7		12.9	13.8	NS	NS	NS	NS	NS	NS
B*13	6.9	14.3		10.3	NS	NS	NS	NS	NS	NS
B*14	3.1		6.5	10.3	NS	NS	NS	NS	NS	NS
B*15	7.6	14.3	6.5	3.5	NS	NS	NS	NS	NS	NS
B*18	16.0	14.3	9.7	6.9	NS	NS	NS	NS	NS	NS
B*27	13.0	14.3	25.8	13.8	NS	NS	NS	NS	0.096* (1.906)	NS
B*35	23.7	57.1	32.3	31.0	NS	NS	NS	0.069* (3.924)	NS	NS
B*38	8.4		9.7	6.9	NS	NS	NS	NS	NS	NS
B*39	3.1		3.2	6.9	NS	NS	NS	NS	NS	NS
B*40	9.9		6.5	6.9	NS	NS	NS	NS	NS	NS
B*41	1.5			3.5	NS	NS	NS	NS	NS	NS
B*44	17.6		29.0	24.1	NS	NS	NS	NS	NS	NS
B*47	0.0			3.5	NS	NS	NS	NS	NS	NS
B*49	4.6		3.2	3.5	NS	NS	NS	NS	NS	NS
B*50	3.1		3.2	6.9	NS	NS	NS	NS	NS	NS
B*51	13.0		12.9	24.1	NS	NS	NS	NS	NS	NS
B*55	4.6	14.3	3.2	3.5	NS	NS	NS	NS	NS	NS
B*57	6.9	28.6	3.2	3.5	0.081* (4.667)	0.090* (4.340)	NS	0.098* (4.618)	NS	NS
DRB1*01	28.2	42.9	34.4	31.3	NS	NS	NS	NS	NS	NS
DRB1*03	23.7		18.8	18.8	NS	NS	NS	NS	NS	NS
DRB1*04	16.0		18.8	21.9	NS	NS	NS	NS	NS	NS
DRB1*07	18.3	28.6	21.9	21.9	NS	NS	NS	NS	NS	NS
DRB1*08	3.1		3.1	9.4	NS	NS	NS	NS	NS	NS
DRB1*11	26.0	42.9	25.0	18.8	NS	NS	NS	NS	NS	NS
DRB1*12	0.8		3.1	6.3	NS	NS	NS	NS	NS	NS
DRB1*13	20.6		18.8	21.9	NS	NS	NS	NS	NS	NS
DRB1*14	8.4	14.3	9.4	15.6	NS	NS	NS	NS	NS	NS
DRB1*15	22.1	14.3	18.8	15.6	NS	NS	NS	NS	NS	NS
DRB1*16	16.0	14.3	9.4	9.4	NS	NS	NS	NS	NS	NS

^aP values between control group and/or groups with indicated outcomes were determined using the two-tailed Fischer's exact test. NS, not significant; *, borderline significant (P < 0.1).